| Title |
Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer
|
|---|---|
| Published in |
Value in Health (Elsevier Science), July 2013
|
| DOI | 10.1016/j.jval.2013.03.1625 |
| Pubmed ID | |
| Authors |
Mike Paulden, Jacob Franek, Ba’ Pham, Philippe L. Bedard, Maureen Trudeau, Murray Krahn |
| Abstract |
Adjuvant chemotherapy decisions in early breast cancer are complex. The 21-gene assay can potentially aid such decisions, but costs US $4175 per patient. Adjuvant! Online is a freely available decision aid. We evaluate the cost-effectiveness of using the 21-gene assay in conjunction with Adjuvant! Online, and of providing adjuvant chemotherapy conditional upon risk classification. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Canada | 2 | 2% |
| Switzerland | 1 | 1% |
| Colombia | 1 | 1% |
| United Kingdom | 1 | 1% |
| Unknown | 74 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 17% |
| Student > Ph. D. Student | 13 | 16% |
| Researcher | 10 | 12% |
| Other | 9 | 11% |
| Student > Postgraduate | 5 | 6% |
| Other | 18 | 22% |
| Unknown | 12 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 26% |
| Economics, Econometrics and Finance | 8 | 10% |
| Nursing and Health Professions | 7 | 9% |
| Agricultural and Biological Sciences | 6 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Other | 17 | 21% |
| Unknown | 17 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2013.
All research outputs
#17,286,379
of 25,374,917 outputs
Outputs from Value in Health (Elsevier Science)
#2,612
of 4,140 outputs
Outputs of similar age
#130,888
of 206,711 outputs
Outputs of similar age from Value in Health (Elsevier Science)
#14
of 42 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,140 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,711 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.